More info
Assay range | 0.781-50 ng/ml |
Sensitivity | 0.7 ng/ml |
Specificity | No cross-reaction with other related substances detected |
Size | 96T |
Storage | Store at 2 - 8ºC. Keep reconstituted standard and detection Ab at -20 ºC |
Assay Principle | Sandwich ELISA |
Sample Volume | 50 µL final volume, dilution factor varies on samples |
Sample Type | plasma, serum, urine, milk, CSF, and cell culture supernatants |
Detection Method | Chromogenic |
Kit Components
1. Recombinant Human Lipoprotein(a) standard: 1 vial
2. One 96-well plate coated with Human Lipoprotein(a) Ab
3. Diluent buffer (10x): 30 mL - 1
4. Biotinylated Human Lipoprotein(a) Ab (50x): 140µL
5. Streptavidin-HRP(100x): 80 µL
6. TMB developing agent: 8 mL x1
7. Stop solution: 12 mL x1
8. Washing solution (20x): 30 mL x2
Background
Lipoprotein(a), also known as Lp(a), is an atherogenic lipoprotein particle formed by an assembly of LDL particles and apo(a) bound to apoB-100 component of LDL. Apo(a), the main constituent of Lp(a), is encoded by hapolipoprotein(a) gene [LPA] in human. Apo(a) proteins vary in size due to a size polymorphism caused by a variable number of so-called kringle IV repeats (KIV-2 VNTR) in the LPA gene. This size variation at the gene level is expressed on the protein level as well, resulting in apo(a) proteins with 10 to > 50 kringle IV repeats (each of the variable kringle IV consists of 114 amino acids). These variable apo(a) sizes are known as "apo(a) isoforms". There is a general inverse correlation between the size of the apo(a) isoform and the Lp(a) plasma concentration. The functions of Lp(a) is mostly unknown, but, it has been shown that Lp(a) competes with plasminogen for its binding site, inhibiting tissue-type plasminogen activator 1 and leading to reduced fibrinolysis. High levels of Lp(a) in the blood is a risk factor for myocardial infarction (MI), coronary heart disease (CHD), cerebrovascular disease (CVD), atherosclerosis, thrombosis, and stroke.